Australian clinical-stage drug development company Noxopharm has announced its DARRT-2 Phase II clinical trial has begun with patient enrollment in the US. It is said to have the potential to revolutionise cancer treatment by achieving cancer reduction without many of the unwanted side effects, cost limitations, and logistical challenges associated with other immunotherapies.
DARRT (Direct and Abscopal Response to Radiotherapy) is an experimental immunotherapy cancer treatment based on the concept of Veyonda, combining with a well-tolerated, low dosage of external beam radiotherapy to trigger an immune response — known as an abscopal response — which may lead to the resolution of tumours.
Since low dose radiotherapy is a common form of cancer therapy, the therapeutic and commercial opportunities of adding Veyonda to transform symptomatic relief into a meaningful tumour response are substantial.
Noxopharm Chief Medical Officer, Dr. Gisela Mautner, said: “The participation of institutions with prestigious radiation and medical oncologists is testament to the potential of the DARRT-treatment.”
Image credit: Noxopharm
